Dr. Anton Titov, MD.: Professor Munshi, you are a world-renowned expert at the precision medicine treatment and immune response in multiple myeloma and new therapists. So, what is the role for immunotherapy and chimeric antigen receptor T cells known as CAR T-cells in treatment of multiple myeloma, I have been treating myeloma for over 30 years and have been through all different treatment development. I have not seen anything like the one which we have seen currently, with CAR T-cell therapy. The responses are incredible. They are fast happens very quickly. Two weeks sometimes in patients who are at a very late stage they will get six and eight and 10 different treatments before they come for CAR T-cells and they all respond. The overall response rate with CAR T-cell product has been at 90%, close to 98% - 99% even at that late stage with 80% patients having complete remission 50% patient having MRD negativity, so incredibly deep responses and frequency of responses we observed with CAR T-cell therapy. Similarly very encouraging results are also with by specific antibodies. So this very specific cellular or a CAR T-cells and by specific treatments are very quickly becoming a standard component or over therapeutic intervention. It's moving so fast in two years. Is to cellular therapies are already approved, they are becoming standard of care for our treatment in relapsed patient populations. And we another cell, number of studies with this CAR T-cells are being utilized earlier on. There are studies ongoing that comparing CAR T-cell therapy with transplant and some other interventions. And so, these treatments are becoming standard therapeutic components for myeloma treatments at an early stage, as well as middle and the late stage of the disease, they'll be part of our treatment before we know it.